DOTA-TOC (DOTA-[Tyr3]-octreotide), precursor for radiolabeled DOTA-TOC and ligand for somatostatin receptors. Can be bound to radionuclides for development of cancer treatment and diagnosis. For research use only! Amino acid sequence: DPhe-Cys-Tyr-DTrp-Lys-Thr-Cys-Thr-ol (cyclic disulfide) Amount: 2 mg (20 x100ug) Purity: >95% (HPLC-MS) Delivery Format: Freeze-dried in glass vial Application(s): Nuclear imaging, Somatostatin receptor scintigraphy (SRS) Indication(s)/Topic(s): Cancer Delivery Time: approx. 3 weeks
JPT's Single Catalog Peptides JPT Peptide Technologies has substantial, long-standing expertise in providing custom peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All of JPT's catalogue peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Benefits of JPT's Single Catalogue Peptides - Whole production performed in a regulated European environment according to DIN EN ISO 9001:2015 & GCLP standards; audits welcome! - Synthesis protocols designed to avoid toxic contaminants and side products - Provision of freeze dried aliquots for enhanced stability - Proven track record for applications in clinical studies
Testimonial "Our group focuses on the in vitro study of risk factors in Alzheimer’s disease and, as we experienced that the in-house expression and production of the amyloid beta peptide is notoriously difficult, we are continuously dependent on a high quality supply of a large variety of these peptides from commercial source.We started our collaboration with JPT with their request to test a range of their peptides for the ability to produce toxic oligomers and fibrillar networks and were impressed by the rapid supply of a very wide range of high purity peptides with excellent fibril forming properties and toxicity profiles. JPT has shown real valuable know-how and experience in the field of peptide synthesis by their ability to generate high quality preparations of amyloid beta peptide variants which are known for their difficulty to handle." Kerensa Broersen, Assistant Prof., Nanobiophysics Group, University of Twente, Enschede, The Netherlands